Levo-carnitine (L-carnitine) is a naturally occurring amino acid derivative essential for the transport of long-chain fatty acids into the mitochondrial matrix for beta-oxidation and energy production. The 500mg/5ml oral solution is a concentrated formulation used to treat primary and secondary carnitine deficiencies, and is widely used in India for various metabolic and cardiovascular conditions. It is a conditionally essential nutrient.
Adult: For deficiency states: 1-3 g per day in divided doses (2-3 times daily). Typical dose: 990 mg to 2 g daily. For the 500mg/5ml solution, this translates to 5-20 ml per day in divided doses. For ESRD on dialysis: 10-20 mg/kg dry body weight post-dialysis (IV route common; oral can be used on non-dialysis days).
Note: Administer orally, preferably with or after meals to improve tolerance and reduce gastrointestinal upset. The solution can be taken directly or diluted in water or juice. Use the measuring cup or syringe provided for accurate dosing. Do not mix with hot beverages. Maintain adequate hydration.
L-carnitine's primary role is to facilitate the transport of activated long-chain fatty acids (as acyl-CoA) across the impermeable inner mitochondrial membrane. It acts as a substrate for carnitine palmitoyltransferase I (CPT I) and II (CPT II), forming acyl-carnitine esters which are shuttled into the mitochondrial matrix. Inside, the acyl group is transferred back to CoA for beta-oxidation, liberating carnitine for reuse. This process is critical for energy production, especially in tissues with high fatty acid demand like cardiac and skeletal muscle.
Pregnancy: Category B. Animal studies show no risk, but adequate human studies are lacking. Use only if clearly needed, such as for documented carnitine deficiency. Endogenous carnitine crosses the placenta.
Driving: No known effects on driving ability. However, if dizziness or nausea occurs, patients should avoid operating machinery.
| Valproic Acid / Valproate | Valproic acid depletes carnitine levels, leading to deficiency. Levo-carnitine supplementation can prevent or treat valproate-induced hyperammonemia and hepatotoxicity. | Major |
| Warfarin | Potential interaction reported; L-carnitine may potentiate the anticoagulant effect of warfarin, increasing INR. Monitor INR closely when starting or stopping carnitine. | Moderate |
| Thyroid Hormones (Levothyroxine) | Theoretical interaction as L-carnitine may inhibit the cellular uptake of thyroid hormone. Clinical significance is unclear but monitor thyroid function in patients on both. | Minor |
| Acitretin | May increase the risk of myopathy. Use with caution. | Moderate |